Louisiana Man Becomes First to Be Functionally Cured of Sickle Cell Disease

A 23-year-old Louisiana man rang the hospital bell to mark a “functional cure” from sickle cell disease after receiving the Casgevy gene-editing therapy, a first for the state.

Story Snapshot

Manning Family Children’s Hospital said Daniel Cressy is functionally cured after Casgevy gene therapy.
The treatment edits a patient’s own blood stem cells to boost fetal hemoglobin and prevent painful crises.
The Food and Drug Administration approved Casgevy and Lyfgenia in 2023 for severe sickle cell disease.
High list prices near or above $2 million raise access and coverage concerns for families and states.

Hospital Confirms First-in-Louisiana Functional Cure

Manning Family Children’s Hospital in New Orleans reported that patient Daniel Cressy completed a more than two-year treatment journey and “rang the bell” on June 22, signaling a functional cure from sickle cell disease. Local outlets and national coverage identified him as the first person in Louisiana, and in the Gulf South, to reach that outcome after gene therapy. The hospital credited Casgevy, a gene-editing treatment, and said the result now lets Cressy resume his goal of becoming a pilot.

Health reporters explained that “functional cure” means the therapy stopped the severe complications that define the disease, especially painful blockages known as vaso-occlusive crises. Doctors at the center guided Cressy through stem cell collection, high-dose treatment to clear bone marrow, and reinfusion of his edited cells. The hospital’s account framed the bell ringing as a milestone for the state and a life-changing moment for the patient and his family.

What Casgevy Does Inside the Body

Casgevy uses clustered regularly interspaced short palindromic repeats with Cas9 to edit a person’s own blood-forming stem cells. The edit drives higher levels of fetal hemoglobin. That fetal hemoglobin prevents red blood cells from taking the rigid, sickled shape that blocks blood flow and triggers pain and organ damage. Peer-reviewed reviews describe strong short- to medium-term drops in severe pain crises and hospital visits in treated patients across studies. These gains align with the hospital’s “functional cure” claim.

The Food and Drug Administration cleared Casgevy and Lyfgenia in December 2023 for patients 12 and older with severe sickle cell disease. Researchers reported high rates of crisis-free status in evaluated patients and improved total hemoglobin levels in follow-up windows that now reach several years for some cohorts. Experts still track long-term safety and durability, as is common for new, intensive therapies, but the near-term efficacy signals are strong and consistent across trials.

Cost, Access, and the Equity Challenge

The Congressional Budget Office noted that each sickle cell gene therapy lists for more than $2 million and requires many steps, including hospital stays and specialized staff. Industry and academic reporting put expected prices in the $2 million to $3 million range, which can strain public and private budgets, especially in states with many patients and limited specialty centers. These costs risk leaving cures on paper while families wait for coverage approvals or travel far for treatment slots.

Patient advocates say sickle cell disease has long faced underfunding and slow drug development despite its heavy burden on families. The Food and Drug Administration’s 2023 approvals marked a rare leap forward for a disease too often ignored by the system. But the scale-up will test coordination between hospitals, insurers, and state programs. Without clear pathways, many eligible patients could miss a therapy that now exists, deepening anger at a health system seen as serving the well-connected first.

Why This First Matters for Louisiana Families

Louisiana health leaders have tracked sickle cell disease through state reporting, and the first functional cure inside the state may speed referrals and planning for more patients. The Manning Family Children’s case gives doctors and insurers a local example to study, including timing from referral to infusion and recovery milestones. Local proof can help teams solve practical hurdles like housing during treatment, caregiver leave, and post-therapy monitoring that large national reports sometimes miss.

For families on both the left and the right, this story shows what is possible when science, care teams, and a patient’s grit align. It also shows where the system still fails. A one-time therapy that can end years of pain should not be a luxury item. Policymakers, hospital leaders, and insurers now face a simple test: turn a first into a fair standard of care, or watch hope stall at the billing desk.